

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently amended) A pharmaceutical ~~association~~ composition characterized by ~~being based in~~ either tinidazole ~~or secnidazole~~ and fluconazol and/or an estereoisomer or an acceptable estereoisomeric mixture thereof, ~~in a relationship of~~ comprising from ~~about 100~~ about 50 to less than 150 mg fluconazole and from about 1000 to less than 2000 tinidazole, ~~or secnidazol, for the preparation of a medication for the treatment of infectious diseases in the female reproductive system.~~
2. (Currently amended) A pharmaceutical composition characterized by ~~being based on a tinidazole~~ secnidazole and fluconazole ~~and/or an estereoisomer or an estereoisomeric mixture of the same, in a relationship~~ comprising from about 50 to less than 150 mg of fluconazole and 1000 mg to less than 2000 mg of ~~secnidazole, tinidazole,~~ secnidazole, ~~for the preparation of a medication in the treatment of infectious diseases in the female reproductive system.~~
3. (Currently amended) The pharmaceutical composition according to claim 2, characterized by ~~the relationship of the pharmaceutical association is of 75% \pm 20% in weight of fluconazoel and 6\$ \pm 20% of secnidazole. tinidazole and the rest of~~ pharmaceutically acceptable vehicles.
4. (Currently amended) The composition according to claim 3, characterized ~~in addition because it can be dosified in a pharmaceutical manner for~~ by oral administration.
5. (Currently amended) The pharmaceutical composition according to claim 3, characterized by a ~~the fact that the composition is administered in~~ tablet form.

6. (Currently amended) The pharmaceutical composition according to claim 2, characterized ~~in addition by the fact that the~~ by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

7. (Withdrawn) A method for the treatment of infectious diseases in the female reproductive system, comprising ~~in~~ giving a patient suffering such a disease a ~~mono~~ single dose ~~in per one~~ day of the pharmaceutical composition ~~mentioned in~~ of Claim 2.

8. (Withdrawn) A method for the treatment of infectious diseases ~~in accordance to~~ with the pharmaceutical composition of claim 7, characterized because wherein the mixed infections infectious disease have has been caused by *Gardnerella Vaginalis*, *Astinomyces*, *Candida*, *Micrococcus*, yeast, *Proteus*, *Micrococcus*, *E. Coli*, *Trichomonas Vaginilis* ~~and or Trichomonas V.~~, ~~micro-organisms present in vaginitis and vaginosis.~~

9. (Withdrawn) The method according to claim 8, characterized by providing the pharmaceutical composition ~~the fact that the composition is provided in a~~ one tablet form.

10. (Withdrawn) The method according to claim 7 characterized by the fact that it the pharmaceutical composition is administered in a ~~mono~~ single dose ~~and~~ containing approximately 112.5 mg of fluconazole and approximately 1.5 g of tinidazole.

11. (Withdrawn) The use of ~~an association of~~ the pharmaceutical compounds of claim 1 ~~which contains fluconazole and tinidazole~~, wherein the active ingredients are ~~to be found in a relationship~~ from 100 to less than 150 mg of fluconazole and from 1000 to less than 2000 mg of tinidazole for the preparation of ~~to prepare~~ a medication useful in the treatment of infectious diseases in the female reproductive system.

12. (Withdrawn) The use according to claim 11, ~~characterized by comprising~~ wherein the pharmaceutical compound comprises 112.5 mg of fluconazole and 1.5 g of tinidazole.